We are live on ! Find out more
MGX icon

Metagenomi Therapeutics
MGX

56 hedge funds and large institutions have $11M invested in Metagenomi Therapeutics in 2025 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

2.04% more ownership

Funds ownership: 15.99% → 18.02% (+2%)

3% less funds holding

Funds holding: 58 → 56 (-2)

23% less capital invested

Capital invested by funds: $14.2M → $11M (-$3.21M)

28% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 18

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
56
Holders Change
-2
Holders Change %
-3.45%
% of All Funds
0.68%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
11
Increased
13
Reduced
18
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$999K
2
Jane Street
Jane Street
New York
+$726K
3
Two Sigma Investments
Two Sigma Investments
New York
+$506K
4
BCM
Bridgeway Capital Management
Texas
+$433K
5
Citadel Advisors
Citadel Advisors
Florida
+$386K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$393K
2
Walleye Capital
Walleye Capital
New York
-$169K
3
Millennium Management
Millennium Management
New York
-$163K
4
JP Morgan Chase
JP Morgan Chase
New York
-$132K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$81K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.06M +$62.2K +28,736 +2%
Renaissance Technologies
2
Renaissance Technologies
New York
$1.02M +$999K +461,400 +276%
CCM
3
Catalio Capital Management
New York
$857K – – –
PLC
4
Peapod Lane Capital
New York
$806K -$35K -16,162 -3%
Two Sigma Investments
5
Two Sigma Investments
New York
$715K +$506K +233,860 +113%
Jane Street
6
Jane Street
New York
$703K +$726K +335,604 +342%
BCM
7
Bridgeway Capital Management
Texas
$641K +$433K +200,000 +102%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$496K +$30.3K +14,018 +5%
PVI
9
Pura Vida Investments
New York
$428K – – –
Millennium Management
10
Millennium Management
New York
$381K -$163K -75,507 -24%
BlackRock
11
BlackRock
New York
$363K +$1.49K +690 +0.3%
Two Sigma Advisers
12
Two Sigma Advisers
New York
$326K +$327K +150,900 +299%
Citadel Advisors
13
Citadel Advisors
Florida
$289K +$386K +178,172 New
State Street
14
State Street
Massachusetts
$195K -$2.4K -1,110 -0.9%
Wells Fargo
15
Wells Fargo
California
$192K +$35.5K +16,402 +16%
RA
16
Resolute Advisors
California
$146K – – –
Marshall Wace
17
Marshall Wace
United Kingdom
$128K -$26.3K -12,169 -13%
Northern Trust
18
Northern Trust
Illinois
$122K +$76.2K +35,198 +88%
XT
19
XTX Topco
Cayman Islands
$112K +$116K +53,778 +353%
Acadian Asset Management
20
Acadian Asset Management
Massachusetts
$105K +$140K +64,875 New
RC
21
RBF Capital
California
$104K -$14.6K -6,759 -10%
Morgan Stanley
22
Morgan Stanley
New York
$96.7K -$393K -181,652 -75%
Man Group
23
Man Group
United Kingdom
$91.5K +$7.81K +3,609 +7%
BP
24
BBR Partners
New York
$86.5K – – –
FAG
25
Fortitude Advisory Group
Washington
$62.8K – – –
1
2 3

MGX Hedge Fund Activity: Q4 2025 in Review

56 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q4 2025, worth a combined $11M — down 23% from $14.2M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new MGX positions and 9 closed out — a net gain of 2 holders — while 13 added to existing stakes and 18 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $999K. The largest seller was Morgan Stanley, cutting an estimated $393K.

  • 56 institutional investors held Metagenomi Therapeutics (MGX) as of Q4 2025, down from 58 in Q3 2025.
  • Funds reported $11M of Metagenomi Therapeutics stock for Q4 2025, down 23% quarter-over-quarter.
  • 11 funds opened new Metagenomi Therapeutics positions in Q4 2025 and 9 closed out, a net change of +2 holders.
  • The largest Metagenomi Therapeutics buyer in Q4 2025 was Renaissance Technologies, an estimated $999K added.
  • The largest Metagenomi Therapeutics seller in Q4 2025 was Morgan Stanley, an estimated $393K sold.

Based on aggregated 13F filings for Q4 2025.